Hepatic Safety Profile of Rivastigmine

Introduction to Rivastigmine Safety

• The American Academy of Family Physicians and the American College of Physicians recommend rivastigmine as a safe option for patients with pre-existing hepatic disease, unlike tacrine which causes severe hepatotoxicity 1, 2

Hepatic Safety Comparison with Tacrine

• Tacrine has a severe but rare adverse effect of hepatic toxicity, requiring liver function tests every two weeks for 16 weeks and then every 3 months 1, 2
• The American College of Physicians notes that tacrine is no longer used in the United States due to its hepatotoxicity 2
• High discontinuation rates of tacrine were observed in clinical trials due to hepatic adverse effects 3

Adverse Effects of Rivastigmine

• The most common adverse effects of rivastigmine are nausea, vomiting, and diarrhea, which are cholinergic gastrointestinal in nature, not hepatic 1, 2
• The American Academy of Family Physicians reports that the rates of withdrawal due to adverse effects are 14% for rivastigmine versus 0-11% for placebo 2
• Vomiting has the highest relative risk (RR 6.06), followed by nausea and diarrhea, according to clinical guidelines 4

Dosing Considerations

• The American Academy of Family Physicians recommends that rivastigmine can be taken with food to reduce dose-dependent adverse effects 1
• Galantamine, in contrast, is contraindicated in patients with hepatic insufficiency 1